Exosome-Based Therapeutic Development Summit on September 23-25, 2025 in Boston, United States

The exosome and extracellular vesicles (EV) fields are on the verge of groundbreaking clinical and commercial breakthroughs with therapeutic progress hailed from key biopharma including Rion, Direct Biologics, Aegle Therapeutics, Aruna Bio, EXO Biologics, and more!

Showcasing the biopharma's industry advancements in 2025, the 7th Exosome-Based Therapeutics Development Summit returns to Boston, with never-before-seen data, covering the end-to-end from discovery through to optimized characterization, scalable manufacturing and clinical output, as the only industry-dedicated Summit to bridge the gap between science and business towards effective regenerative and precision medicines.

Join 80+ key exosome and extra-cellular vesicle experts specializing in Exosome Biology, R AND D, CMC to Business Development for an unrivalled learning and networking opportunity to roadmap the therapeutic efficacy and delivery potential of exosomes and EVs towards commercialization and patients in need.

URLs:

Tickets: https://go.evvnt.com/3079148-1?pid=10008

Brochure: https://go.evvnt.com/3079148-2?pid=10008

Time: 8:30 AM - 5:00 PM

Prices:

Conference + Focus Day - Industry Pricing*: USD 4197.00,

Conference + Focus Day - Academic Pricing**: USD 3597.00,

Conference + Focus Day - Solution Provider Pricing: USD 5097.00,

Conference Only - Industry Pricing*: USD 2999.00,

Conference Only - Academic Pricing**: USD 2599.00,

Conference Only - Solution Provider Pricing: USD 3699.00

Speakers: Bryan Allinson, Co-Founder and Chief Executive Officer, Vanquish Bio, Chris Paradise, Vice President - Research and Development, Rion, Christopher Locher, Chief Executive Officer and Co-Founder, Versatope Therapeutics, Clayton Deighan, Sales and Applications Manager, Nano FCM, Doug Arm, Chief Operating Officer, EV Therapeutics, Fatah Kashanchi, Professor of Virology, George Mason University, Gianluca Roma, Chief Executive Officer, EV Therapeutics, Hans Hofland, Senior Vice President - Preclinical Development, Turn Biotechnologies, Ina Sarel, Head of Chemistry, Manufacturing, Controls, Quality and Regulatory, NurExone Biologic, Inkyu Lee, R AND D Senior Researcher and Business Development Senior Manager, Shiftbio, Jacki Kornbluth, Co-Founder and Chair for Scientific Advisory Board, Vanquish Bio, Jahan Jowharchi, Chief Technical Operations, Rion, Joseph Barendt, Senior Director of Business Development, Daicel Life Sciences, Kenichi Tamura, Head of CMC Development, Exorphia, Kristin Luther, Vice President of CMC and Analytics, AGS Therapeutics, Kuldeep Neote, Chief Executive Officer, Diadem Biotherapeutics, Mafalda Cacciottolo, Director - Exosome Research, Capricor Therapeutics, Mickey Pentecost, Chief Scientific Officer, Diadem Biotherapeutics, Nicolas Rousseau, Co-Founder and Chief Operating Officer, EVerZom, Phong Le, Professor of Microbiology and Immunology and Cancer Biology, Loyola University Chicago, Pranav Sharma, Founder and Chief Executive Officer, Xosomix, R. Kenneth, Marcus Professor of Chemistry, Clemson University, Sandrine Mores, Chief Operation Officer, EXO Biologics, Shelley Hartman, Chief Executive Officer, Aegle Therapeutics, Steven Jay, Associate Professor, University of Maryland, Steven Stice, Co-Founder and Chief Scientific Officer, ArunA Bio, Timothy Moseley, Chief Scientific Officer, Direct Biologics, Xenia Sango, Chief Executive Officer and Managing Director, VivaZome Therapeutics, Xinjun He, Chief Scientific Officer and Senior Vice President, VesiCURE Therapeutics